Moderna Says Phase 1 Trials Show COVID-19 Vaccine Safe

The pharmaceutical company Moderna announced that its COVID-19 vaccine candidate mRNA-1273 provoked immune responses in all 45 volunteers in the first phase of the trial. Volunteers who got two doses of mRNA-1273 produced more virus-killing anti-bodies than people who recovered from COVID-19. No serious side-effects of the vaccine have been reported but some volunteers reported mild side-effects.